JP2023100904A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023100904A5 JP2023100904A5 JP2023077666A JP2023077666A JP2023100904A5 JP 2023100904 A5 JP2023100904 A5 JP 2023100904A5 JP 2023077666 A JP2023077666 A JP 2023077666A JP 2023077666 A JP2023077666 A JP 2023077666A JP 2023100904 A5 JP2023100904 A5 JP 2023100904A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- antidepressant
- use according
- ketamine
- antipsychotic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000935 antidepressant agent Substances 0.000 claims 9
- 229940005513 antidepressants Drugs 0.000 claims 9
- 239000000203 mixture Substances 0.000 claims 9
- 230000001430 anti-depressive effect Effects 0.000 claims 6
- -1 Citryri) Chemical compound 0.000 claims 4
- 230000000561 anti-psychotic effect Effects 0.000 claims 3
- 229960003299 ketamine Drugs 0.000 claims 3
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 claims 2
- GJJFMKBJSRMPLA-HIFRSBDPSA-N (1R,2S)-2-(aminomethyl)-N,N-diethyl-1-phenyl-1-cyclopropanecarboxamide Chemical compound C=1C=CC=CC=1[C@@]1(C(=O)N(CC)CC)C[C@@H]1CN GJJFMKBJSRMPLA-HIFRSBDPSA-N 0.000 claims 2
- DYDCUQKUCUHJBH-UWTATZPHSA-N D-Cycloserine Chemical compound N[C@@H]1CONC1=O DYDCUQKUCUHJBH-UWTATZPHSA-N 0.000 claims 2
- DYDCUQKUCUHJBH-UHFFFAOYSA-N D-Cycloserine Natural products NC1CONC1=O DYDCUQKUCUHJBH-UHFFFAOYSA-N 0.000 claims 2
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 claims 2
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 claims 2
- RKHCTAKUYDTFHE-QMMMGPOBSA-N ly-156,735 Chemical compound C1=C(Cl)C(OC)=CC2=C1NC=C2[C@@H](C)CNC(C)=O RKHCTAKUYDTFHE-QMMMGPOBSA-N 0.000 claims 2
- 229960002296 paroxetine Drugs 0.000 claims 2
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 2
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 claims 2
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 claims 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims 2
- 229960002073 sertraline Drugs 0.000 claims 2
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 claims 2
- 229960002263 vortioxetine Drugs 0.000 claims 2
- YQNWZWMKLDQSAC-UHFFFAOYSA-N vortioxetine Chemical compound CC1=CC(C)=CC=C1SC1=CC=CC=C1N1CCNCC1 YQNWZWMKLDQSAC-UHFFFAOYSA-N 0.000 claims 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 claims 1
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 claims 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 claims 1
- ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 claims 1
- YQEZLKZALYSWHR-ZDUSSCGKSA-N (S)-ketamine Chemical compound C=1C=CC=C(Cl)C=1[C@@]1(NC)CCCCC1=O YQEZLKZALYSWHR-ZDUSSCGKSA-N 0.000 claims 1
- HXTGXYRHXAGCFP-OAQYLSRUSA-N (r)-(2,3-dimethoxyphenyl)-[1-[2-(4-fluorophenyl)ethyl]piperidin-4-yl]methanol Chemical compound COC1=CC=CC([C@H](O)C2CCN(CCC=3C=CC(F)=CC=3)CC2)=C1OC HXTGXYRHXAGCFP-OAQYLSRUSA-N 0.000 claims 1
- IUVSEUFHPNITEQ-UHFFFAOYSA-N 1-(2,3-dihydro-1,4-benzodioxin-5-yl)-4-[[5-(4-fluorophenyl)pyridin-3-yl]methyl]piperazine Chemical compound C1=CC(F)=CC=C1C1=CN=CC(CN2CCN(CC2)C=2C=3OCCOC=3C=CC=2)=C1 IUVSEUFHPNITEQ-UHFFFAOYSA-N 0.000 claims 1
- 102100036321 5-hydroxytryptamine receptor 2A Human genes 0.000 claims 1
- 101710138091 5-hydroxytryptamine receptor 2A Proteins 0.000 claims 1
- ZRXBCXGGXCXHCB-UHFFFAOYSA-N 7-[4-[2-(2,4-difluorophenyl)ethyl]piperazine-1-carbonyl]-1h-indole-3-carbonitrile Chemical compound FC1=CC(F)=CC=C1CCN1CCN(C(=O)C=2C=3NC=C(C=3C=CC=2)C#N)CC1 ZRXBCXGGXCXHCB-UHFFFAOYSA-N 0.000 claims 1
- GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 claims 1
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 claims 1
- RONZAEMNMFQXRA-INIZCTEOSA-N LSM-5894 Chemical compound C1C2=CC=CN=C2N2CCN(C)C[C@H]2C2=CC=CC=C21 RONZAEMNMFQXRA-INIZCTEOSA-N 0.000 claims 1
- UEQUQVLFIPOEMF-UHFFFAOYSA-N Mianserin Chemical compound C1C2=CC=CC=C2N2CCN(C)CC2C2=CC=CC=C21 UEQUQVLFIPOEMF-UHFFFAOYSA-N 0.000 claims 1
- KYYIDSXMWOZKMP-UHFFFAOYSA-N O-desmethylvenlafaxine Chemical compound C1CCCCC1(O)C(CN(C)C)C1=CC=C(O)C=C1 KYYIDSXMWOZKMP-UHFFFAOYSA-N 0.000 claims 1
- 229960002629 agomelatine Drugs 0.000 claims 1
- YJYPHIXNFHFHND-UHFFFAOYSA-N agomelatine Chemical compound C1=CC=C(CCNC(C)=O)C2=CC(OC)=CC=C21 YJYPHIXNFHFHND-UHFFFAOYSA-N 0.000 claims 1
- 229960000836 amitriptyline Drugs 0.000 claims 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 claims 1
- 229960002519 amoxapine Drugs 0.000 claims 1
- QWGDMFLQWFTERH-UHFFFAOYSA-N amoxapine Chemical compound C12=CC(Cl)=CC=C2OC2=CC=CC=C2N=C1N1CCNCC1 QWGDMFLQWFTERH-UHFFFAOYSA-N 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 239000000164 antipsychotic agent Substances 0.000 claims 1
- 230000036765 blood level Effects 0.000 claims 1
- ZKIAIYBUSXZPLP-UHFFFAOYSA-N brexpiprazole Chemical compound C1=C2NC(=O)C=CC2=CC=C1OCCCCN(CC1)CCN1C1=CC=CC2=C1C=CS2 ZKIAIYBUSXZPLP-UHFFFAOYSA-N 0.000 claims 1
- 229960001210 brexpiprazole Drugs 0.000 claims 1
- 229960001058 bupropion Drugs 0.000 claims 1
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 claims 1
- 229960001653 citalopram Drugs 0.000 claims 1
- 229960004606 clomipramine Drugs 0.000 claims 1
- PSPGQHXMUKWNDI-UHFFFAOYSA-N coluracetam Chemical compound C=12C(C)=C(C)OC2=NC=2CCCCC=2C=1NC(=O)CN1CCCC1=O PSPGQHXMUKWNDI-UHFFFAOYSA-N 0.000 claims 1
- 229950000190 coluracetam Drugs 0.000 claims 1
- 229960005217 dapoxetine Drugs 0.000 claims 1
- USRHYDPUVLEVMC-FQEVSTJZSA-N dapoxetine Chemical compound C1([C@H](CCOC=2C3=CC=CC=C3C=CC=2)N(C)C)=CC=CC=C1 USRHYDPUVLEVMC-FQEVSTJZSA-N 0.000 claims 1
- SRPXSILJHWNFMK-MEDUHNTESA-N dasotraline Chemical compound C1([C@@H]2CC[C@H](C3=CC=CC=C32)N)=CC=C(Cl)C(Cl)=C1 SRPXSILJHWNFMK-MEDUHNTESA-N 0.000 claims 1
- 229960003914 desipramine Drugs 0.000 claims 1
- 229960001623 desvenlafaxine Drugs 0.000 claims 1
- 229960002866 duloxetine Drugs 0.000 claims 1
- VAIOZOCLKVMIMN-PRJWTAEASA-N eplivanserin Chemical compound C=1C=CC=C(F)C=1\C(=N/OCCN(C)C)\C=C\C1=CC=C(O)C=C1 VAIOZOCLKVMIMN-PRJWTAEASA-N 0.000 claims 1
- 229950000789 eplivanserin Drugs 0.000 claims 1
- WSEQXVZVJXJVFP-FQEVSTJZSA-N escitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-FQEVSTJZSA-N 0.000 claims 1
- 229960004341 escitalopram Drugs 0.000 claims 1
- RONZAEMNMFQXRA-MRXNPFEDSA-N esmirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)C[C@@H]2C2=CC=CC=C21 RONZAEMNMFQXRA-MRXNPFEDSA-N 0.000 claims 1
- 229960002464 fluoxetine Drugs 0.000 claims 1
- 229960004038 fluvoxamine Drugs 0.000 claims 1
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 claims 1
- 229960004801 imipramine Drugs 0.000 claims 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical group C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 claims 1
- 229950002473 indalpine Drugs 0.000 claims 1
- SADQVAVFGNTEOD-UHFFFAOYSA-N indalpine Chemical compound C=1NC2=CC=CC=C2C=1CCC1CCNCC1 SADQVAVFGNTEOD-UHFFFAOYSA-N 0.000 claims 1
- 229940125425 inverse agonist Drugs 0.000 claims 1
- GJJFMKBJSRMPLA-DZGCQCFKSA-N levomilnacipran Chemical compound C=1C=CC=CC=1[C@]1(C(=O)N(CC)CC)C[C@H]1CN GJJFMKBJSRMPLA-DZGCQCFKSA-N 0.000 claims 1
- 229960000685 levomilnacipran Drugs 0.000 claims 1
- VOBHXZCDAVEXEY-JSGCOSHPSA-N lisdexamfetamine Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](C)CC1=CC=CC=C1 VOBHXZCDAVEXEY-JSGCOSHPSA-N 0.000 claims 1
- 229960001451 lisdexamfetamine Drugs 0.000 claims 1
- 229960004090 maprotiline Drugs 0.000 claims 1
- QSLMDECMDJKHMQ-GSXCWMCISA-N maprotiline Chemical compound C12=CC=CC=C2[C@@]2(CCCNC)C3=CC=CC=C3[C@@H]1CC2 QSLMDECMDJKHMQ-GSXCWMCISA-N 0.000 claims 1
- 229960003955 mianserin Drugs 0.000 claims 1
- 229960000600 milnacipran Drugs 0.000 claims 1
- 229960001785 mirtazapine Drugs 0.000 claims 1
- RONZAEMNMFQXRA-UHFFFAOYSA-N mirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 claims 1
- 229960001800 nefazodone Drugs 0.000 claims 1
- VRBKIVRKKCLPHA-UHFFFAOYSA-N nefazodone Chemical compound O=C1N(CCOC=2C=CC=CC=2)C(CC)=NN1CCCN(CC1)CCN1C1=CC=CC(Cl)=C1 VRBKIVRKKCLPHA-UHFFFAOYSA-N 0.000 claims 1
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 claims 1
- 229960002748 norepinephrine Drugs 0.000 claims 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 claims 1
- 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 claims 1
- RKEWSXXUOLRFBX-UHFFFAOYSA-N pimavanserin Chemical compound C1=CC(OCC(C)C)=CC=C1CNC(=O)N(C1CCN(C)CC1)CC1=CC=C(F)C=C1 RKEWSXXUOLRFBX-UHFFFAOYSA-N 0.000 claims 1
- 229960004431 quetiapine Drugs 0.000 claims 1
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 claims 1
- 239000002469 receptor inverse agonist Substances 0.000 claims 1
- RNRYULFRLCBRQS-UHFFFAOYSA-N roluperidone Chemical compound C1=CC(F)=CC=C1C(=O)CN1CCC(CN2C(C3=CC=CC=C3C2)=O)CC1 RNRYULFRLCBRQS-UHFFFAOYSA-N 0.000 claims 1
- 229940076279 serotonin Drugs 0.000 claims 1
- 239000002400 serotonin 2A antagonist Substances 0.000 claims 1
- 239000003762 serotonin receptor affecting agent Substances 0.000 claims 1
- 239000003772 serotonin uptake inhibitor Substances 0.000 claims 1
- 229950002275 setiptiline Drugs 0.000 claims 1
- GVPIXRLYKVFFMK-UHFFFAOYSA-N setiptiline Chemical compound C12=CC=CC=C2CC2=CC=CC=C2C2=C1CN(C)CC2 GVPIXRLYKVFFMK-UHFFFAOYSA-N 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 229960003991 trazodone Drugs 0.000 claims 1
- PHLBKPHSAVXXEF-UHFFFAOYSA-N trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 claims 1
- 229960004688 venlafaxine Drugs 0.000 claims 1
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 claims 1
- QYRYFNHXARDNFZ-UHFFFAOYSA-N venlafaxine hydrochloride Chemical compound [H+].[Cl-].C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 QYRYFNHXARDNFZ-UHFFFAOYSA-N 0.000 claims 1
- 229960003740 vilazodone Drugs 0.000 claims 1
- SGEGOXDYSFKCPT-UHFFFAOYSA-N vilazodone Chemical compound C1=C(C#N)C=C2C(CCCCN3CCN(CC3)C=3C=C4C=C(OC4=CC=3)C(=O)N)=CNC2=C1 SGEGOXDYSFKCPT-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762510801P | 2017-05-25 | 2017-05-25 | |
| US62/510,801 | 2017-05-25 | ||
| US201762518020P | 2017-06-12 | 2017-06-12 | |
| US62/518,020 | 2017-06-12 | ||
| JP2019564988A JP7312116B2 (ja) | 2017-05-25 | 2018-05-24 | 外傷後ストレス障害の治療用の製剤 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019564988A Division JP7312116B2 (ja) | 2017-05-25 | 2018-05-24 | 外傷後ストレス障害の治療用の製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023100904A JP2023100904A (ja) | 2023-07-19 |
| JP2023100904A5 true JP2023100904A5 (https=) | 2023-08-30 |
| JP7537675B2 JP7537675B2 (ja) | 2024-08-21 |
Family
ID=64396350
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019564867A Active JP7308761B2 (ja) | 2017-05-25 | 2018-05-24 | Ｎｍｄａｒアンタゴニスト－応答性精神神経障害のための併用療法 |
| JP2019564988A Active JP7312116B2 (ja) | 2017-05-25 | 2018-05-24 | 外傷後ストレス障害の治療用の製剤 |
| JP2023034164A Active JP7585369B2 (ja) | 2017-05-25 | 2023-03-07 | Ｎｍｄａｒアンタゴニスト－応答性精神神経障害のための併用療法 |
| JP2023077666A Active JP7537675B2 (ja) | 2017-05-25 | 2023-05-10 | 外傷後ストレス障害の治療用の製剤 |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019564867A Active JP7308761B2 (ja) | 2017-05-25 | 2018-05-24 | Ｎｍｄａｒアンタゴニスト－応答性精神神経障害のための併用療法 |
| JP2019564988A Active JP7312116B2 (ja) | 2017-05-25 | 2018-05-24 | 外傷後ストレス障害の治療用の製剤 |
| JP2023034164A Active JP7585369B2 (ja) | 2017-05-25 | 2023-03-07 | Ｎｍｄａｒアンタゴニスト－応答性精神神経障害のための併用療法 |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US20180338956A1 (https=) |
| EP (2) | EP3630103B1 (https=) |
| JP (4) | JP7308761B2 (https=) |
| KR (2) | KR102608479B1 (https=) |
| CN (2) | CN110996947A (https=) |
| AU (2) | AU2018274767A1 (https=) |
| BR (2) | BR112019024817A2 (https=) |
| CA (2) | CA3064846A1 (https=) |
| IL (2) | IL270916B2 (https=) |
| MX (2) | MX394875B (https=) |
| RU (2) | RU2019143572A (https=) |
| WO (2) | WO2018216020A1 (https=) |
| ZA (2) | ZA201908616B (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3043785T1 (sl) | 2013-09-13 | 2022-02-28 | National University Corporation Chiba University | Uporaba R-ketamina in njegove soli kot farmacevtska sredstva |
| RU2019143572A (ru) * | 2017-05-25 | 2021-06-25 | Глитек Ллс. | Композиции для лечения посттравматического стрессового расстройства |
| PL3505157T3 (pl) | 2017-12-29 | 2022-04-11 | Celon Pharma S.A. | Kompozycja ketaminy w postaci suchego proszku do podawania dopłucnego w leczeniu depresji opornej na leczenie |
| JP7548669B2 (ja) | 2018-02-15 | 2024-09-10 | 国立大学法人千葉大学 | 炎症性疾患若しくは骨疾患の予防又は治療剤及び医薬組成物 |
| AU2019262197B2 (en) | 2018-05-04 | 2024-12-19 | Perception Neuroscience, Inc. | Methods of treating substance abuse |
| WO2020092496A1 (en) * | 2018-10-31 | 2020-05-07 | Sunovion Pharmaceuticals Inc. | Methods of treating central nervous system disorders |
| CN114007600A (zh) * | 2019-04-09 | 2022-02-01 | 维斯塔津治疗公司 | 与神经系统病症的治疗响应有关的遗传变异 |
| US20230017786A1 (en) * | 2020-01-03 | 2023-01-19 | University Of Padova | Dextromethadone as a disease-modifying treatment for neuropsychiatric disorders and diseases |
| CN115677519A (zh) * | 2021-07-22 | 2023-02-03 | 立科时代(武汉)生物科技有限公司 | L-4-溴-犬尿氨酸及其在制备治疗抑郁症药物中的应用 |
| CN113648320A (zh) * | 2021-08-16 | 2021-11-16 | 中国人民解放军军事科学院军事医学研究院 | 赛洛西宾抗创伤后应激障碍的医药用途 |
| EP4709379A1 (en) * | 2023-06-29 | 2026-03-18 | The Sarah Herzog Memorial Hospital-Ezrath Nashim | Nmdar antagonist for the treatment of inflammatory diseases in patients with depression comorbidity |
| US12303604B1 (en) | 2024-10-16 | 2025-05-20 | Currax Pharmaceuticals Llc | Pharmaceutical formulations comprising naltrexone and/or bupropion |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6391922B1 (en) | 1998-01-13 | 2002-05-21 | Synchroneuron, Llc | Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders |
| DE1073432T1 (de) | 1998-04-14 | 2002-02-07 | The General Hospital Corp., Boston | Verwendung von glycinrezeptoragonisten und glycinaufnahmeinhibitoren zur behandlung neuropsychiatrischer beschwerden |
| US20050096396A1 (en) * | 2002-03-28 | 2005-05-05 | Emory University | Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning |
| WO2005016319A2 (en) | 2003-08-06 | 2005-02-24 | Emory University | Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning |
| DK2009000T3 (da) | 2003-01-16 | 2011-09-05 | Acadia Pharm Inc | Selektive serotonin 2A/2C-receptor invers-agonister som terapeutika for neurodegenerative sygdomme |
| US7838029B1 (en) * | 2003-07-31 | 2010-11-23 | Watson Laboratories, Inc. | Mirtazapine solid dosage forms |
| EP1734920A2 (en) | 2004-02-13 | 2006-12-27 | Neuromolecular Inc. | Combination of a nmda receptor antagonist and an mao-inhibitor or a gadph-inhibitor for the treatment of psychiatric conditions |
| US20050261278A1 (en) | 2004-05-21 | 2005-11-24 | Weiner David M | Selective serotonin receptor inverse agonists as therapeutics for disease |
| US7820695B2 (en) | 2004-05-21 | 2010-10-26 | Acadia Pharmaceuticals, Inc. | Selective serotonin receptor inverse agonists as therapeutics for disease |
| CA2580129A1 (en) | 2004-09-27 | 2006-04-06 | Acadia Pharmaceuticals Inc. | Salts of n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n'-(4-(2-methylpropyloxy)phenylmethyl)carbamide and their preparation |
| TW200631584A (en) | 2004-11-15 | 2006-09-16 | Akzo Nobel Nv | A medicament related to mirtazapine for the treatment of hot flush |
| CA2672494A1 (en) | 2006-12-14 | 2008-06-19 | Nps Pharmaceuticals, Inc. | Use of d-serine derivatives for the treatment of anxiety disorders |
| WO2010099217A1 (en) * | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| US9789093B2 (en) | 2011-01-31 | 2017-10-17 | Serotech, Llc | Dosage regimen, medication dispensing package and uses thereof for the treatment of major depressive disorder |
| US9737531B2 (en) * | 2012-07-12 | 2017-08-22 | Glytech, Llc | Composition and method for treatment of depression and psychosis in humans |
| EP2841063A2 (en) | 2012-04-27 | 2015-03-04 | Indiana University Research and Technology Corporation | Compositions and methods for treating ptsd and related diseases |
| LT3057595T (lt) * | 2013-10-18 | 2020-08-10 | Emalex Biosciences, Inc. | Sintezuoti benzazepinai, skirti mikčiojimui gydyti |
| EP3197440A4 (en) | 2014-09-22 | 2018-04-18 | Rugen Holdings (Cayman) Limited | Treatment of anxiety disorders and autism spectrum disorders |
| WO2016061320A2 (en) | 2014-10-15 | 2016-04-21 | Rowan University | Timber therapy for post-traumatic stress disorder |
| HK1255584A1 (zh) | 2015-08-04 | 2019-08-23 | Confluence Pharmaceuticals, Llc | 使用阿坎酸及d-环丝胺酸的联合疗法 |
| US20190054067A1 (en) * | 2016-03-15 | 2019-02-21 | University Of The Sciences | Compositions and methods for treating compulsive-like behavior in a subject |
| RU2019143572A (ru) * | 2017-05-25 | 2021-06-25 | Глитек Ллс. | Композиции для лечения посттравматического стрессового расстройства |
-
2018
- 2018-05-24 RU RU2019143572A patent/RU2019143572A/ru not_active Application Discontinuation
- 2018-05-24 CA CA3064846A patent/CA3064846A1/en active Pending
- 2018-05-24 AU AU2018274767A patent/AU2018274767A1/en not_active Abandoned
- 2018-05-24 KR KR1020197038209A patent/KR102608479B1/ko active Active
- 2018-05-24 KR KR1020197038205A patent/KR102654569B1/ko active Active
- 2018-05-24 EP EP18806042.0A patent/EP3630103B1/en active Active
- 2018-05-24 CA CA3065003A patent/CA3065003A1/en active Pending
- 2018-05-24 MX MX2019014113A patent/MX394875B/es unknown
- 2018-05-24 JP JP2019564867A patent/JP7308761B2/ja active Active
- 2018-05-24 IL IL270916A patent/IL270916B2/en unknown
- 2018-05-24 JP JP2019564988A patent/JP7312116B2/ja active Active
- 2018-05-24 US US15/987,941 patent/US20180338956A1/en not_active Abandoned
- 2018-05-24 EP EP18805411.8A patent/EP3630102B1/en active Active
- 2018-05-24 AU AU2018274765A patent/AU2018274765A1/en not_active Abandoned
- 2018-05-24 IL IL270885A patent/IL270885B2/en unknown
- 2018-05-24 US US15/987,933 patent/US10881665B2/en active Active
- 2018-05-24 CN CN201880048653.3A patent/CN110996947A/zh active Pending
- 2018-05-24 BR BR112019024817-0A patent/BR112019024817A2/pt active Search and Examination
- 2018-05-24 RU RU2019143573A patent/RU2019143573A/ru not_active Application Discontinuation
- 2018-05-24 BR BR112019024802-1A patent/BR112019024802A2/pt unknown
- 2018-05-24 WO PCT/IL2018/050570 patent/WO2018216020A1/en not_active Ceased
- 2018-05-24 WO PCT/IL2018/050567 patent/WO2018216018A1/en not_active Ceased
- 2018-05-24 CN CN201880048442.XA patent/CN110996946A/zh active Pending
- 2018-05-24 MX MX2019014114A patent/MX394876B/es unknown
-
2019
- 2019-12-23 ZA ZA2019/08616A patent/ZA201908616B/en unknown
- 2019-12-23 ZA ZA2019/08617A patent/ZA201908617B/en unknown
-
2021
- 2021-01-01 US US17/139,999 patent/US11969431B2/en active Active
-
2022
- 2022-01-28 US US17/586,828 patent/US20220143041A1/en active Pending
-
2023
- 2023-03-07 JP JP2023034164A patent/JP7585369B2/ja active Active
- 2023-05-10 JP JP2023077666A patent/JP7537675B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023100904A5 (https=) | ||
| RU2019143572A (ru) | Композиции для лечения посттравматического стрессового расстройства | |
| US20090306137A1 (en) | Treatment for depressive disorders | |
| JP2009538331A5 (https=) | ||
| RU2012152922A (ru) | Лечение психологических состояний с применением антагонистов м1-мускариновых рецепторов | |
| CN101198322A (zh) | 用于治疗或预防抑郁症的新治疗组合 | |
| JP2012036212A5 (https=) | ||
| JP2009542819A5 (https=) | ||
| JP5371762B2 (ja) | ムスカリン性受容体ｍ１拮抗薬による肥満の処置 | |
| JP2009542820A5 (https=) | ||
| CN101472476B (zh) | 毒蕈碱型受体m1拮抗剂在制备治疗肥胖症的药物中的应用 | |
| JPWO2023158668A5 (https=) | ||
| JP2007513896A5 (https=) | ||
| RU2009101146A (ru) | Лечение ожирения антагонистами мускаринового рецептора м1 | |
| JPWO2023067505A5 (https=) | ||
| FR2912057A1 (fr) | Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine | |
| RU2024139942A (ru) | Подкожное введение онфаспродила и способы введения доз для применения в лечении депрессивных расстройств | |
| RU2019123563A (ru) | Новые комбинации антагонистов н3-рецепторов и ингибиторов обратного захвата норадреналина и их терапевтическое применение | |
| US20080182899A1 (en) | Association of beta3 receptor agonist and monoamine reuptake inhibitors, pharmaceutical composition and therapeutic use thereof |